Abstract
Two novel half-sandwich organometallic complexes, [(p-cymene)-M-(XY)-Cl], XY = L-BSO, M = Ru(II) (Ru-LBSO), Os(II) (Os-LBSO), containing the amino acid L-buthionine sulfoximine (L-BSO), as well as their XY = glycine analogs (Ru-Gly and Os-Gly), have been synthesized, characterized and their solution chemistry investigated. L-BSO is an inhibitor of the enzyme γ-glutamyl cysteine synthetase and, hence, glutathione synthesis. The diastereomers of Ru-LBSO and Os-LBSO were also characterized by DFT calculations which suggested the higher stability of [S(M),r(S)] and [S(M),s(S)] compared to [R(M),r(S)] and [R(M),s(S)] configurations [chirality at M-(II), chirality at sulfur of L-BSO]. Interestingly, glycine complexes are non-toxic toward both cancer and normal cells, whereas Os-LBSO was cytotoxic toward human IGROV-1 ovarian cancer cells, but not toward lung and cervical cancer cells. Os-LBSO, but not Ru-LBSO, demonstrated glutathione inhibition. These studies on Ru-LBSO and Os-LBSO complexes demonstrate the challenges of making progress toward the development for clinical use of organometallic complexes that contain multiple chiral centers. However, they offer exciting possibilities for discovery of novel drugs with new mechanisms of action.